This narrative review critically examines current HF pharmacotherapy in the context of AF, focusing on the four cornerstone treatments and modifiers of prognosis for HF with reduced ejection fraction: beta‐blockers, angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers/sacubitril‐valsartan, aldosterone antagonists, and sodium–glucose co‐transporter 2 inhibitors. Here, ACE is linked to atrial fibrillation.